Trafficking, turnover and membrane topology of PrP

British Medical Bulletin

Volumn 66, Issue , 2003, Pages 71-85

  Harris, David A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN; COPPER ION; PRION PROTEIN; PROTEASOME;

BIOCHEMISTRY; CELL MATURATION; CELL SURFACE; CELLULAR DISTRIBUTION; CYTOLOGY; ENDOPLASMIC RETICULUM; ENDOSOME; GENE MUTATION; GOLGI COMPLEX; HUMAN; INHERITANCE; MEMBRANE STRUCTURE; NEUROTOXICITY; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN TRANSPORT; REVIEW; TRANSLATION REGULATION;

ANIMALS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; CLATHRIN-COATED VESICLES; COPPER; CYTOSOL; ENDOPLASMIC RETICULUM; GOLGI APPARATUS; HUMANS; MUTATION; NEURONS; PRION DISEASES; PRPC PROTEINS;

EID: 0141626391     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/66.1.71     Document Type: Review

References (66)

1. Stahl N, Borchelt DR, Hsiao K, Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987; 51: 229-49
2. Turk E, Teplow DB, Hood LE, Prusiner SB. Purification and properties of the cellular and scrapie hamster prion proteins. Eur J Biochem 1988; 176: 21-30
3. Haraguchi T, Fisher S, Olofsson S et al. Asparagine-linked glycosylation of the scrapie and cellular prion proteins. Arch Biochem Biophys 1989; 274: 1-13
4. Shyng SL, Huber MT, Harris DA. A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells. J Biol Chem 1993; 268: 15922-8
5. Harris DA, Huber MT, van Dijken P, Shyng S-L, Chait BT, Wang R. Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. Biochemistry 1993; 32: 1009-16
6. Magalhães AC, Silva JA, Lee KS et al. Endocytic intermediates involved with the intracellular trafficking of a fluorescent cellular prion protein. J Biol Chem 2002; 277: 33311-8
7. Borchelt DR, Taraboulos A, Prusiner SB. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J Biol Chem 1992; 267: 16188-99
8. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 1991; 266: 18217-23
9. Shyng SL, Heuser JE, Harris DA. A glycolipid-anchored prion protein is endocytosed via clathrin-coated pits. J Cell Biol 1994; 125: 1239-50
10. Madore N, Smith KL, Graham CH et al. Functionally different GPI proteins are organized in different domains on the neuronal surface. EMBO J 1999; 18: 6917-26
11. Lainé J, Marc ME, Sy MS, Axelrad H. Cellular and subcellular morphological localization of normal prion protein in rodent cerebellum. Eur J Neurosci 2001; 14: 47-56
12. Shyng SL, Moulder KL, Lesko A, Harris DA. The N-terminal domain of a glycolipid-anchored prion protein is essential for its endocytosis via clathrin-coated pits. J Biol Chem 1995; 270: 14793-800
13. Nunziante M, Gilch S, Schatzl HM. Essential role of the prion protein N-terminus in subcellular trafficking and half-life of PrPc. J Biol Chem 2002; 10.1074/jbc.M206313200
14. Lee KS, Magalhaes AC, Zanata SM, Brentani RR, Martins VR, Prado MA. Internalization of mammalian fluorescent cellular prion protein and N-terminal deletion mutants in living cells. J Neurochem 2001; 79: 79-87
15. Harris DA, Gorodinsky A, Lehmann S, Moulder K, Shyng S-L. Cell biology of the prion protein. Curr Top Microbiol Immunol 1996; 207: 77-93
16. Gauczynski S, Peyrin JM, Haik S et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001; 20: 5863-75
17. Zanata SM, Lopes MH, Mercadante AF et al. Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. EMBO J 2002; 21: 3307-16
18. Gorodinsky A, Harris DA. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J Cell Biol 1995; 129: 619-27
19. Vey M, Pilkuhn S, Wille H et al. Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci USA 1996; 93: 14945-9
20. Naslavsky N, Stein R, Yanai A, Friedlander G, Taraboulos A. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J Biol Chem 1996; 272: 6324-31
21. Mouillet-Richard S, Ermonval M, Chebassier C et al. Signal transduction through prion protein. Science 2000; 289: 1925-8
22. Taraboulos A, Scott M, Semenov A et al. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 1995; 129: 121-32
23. Stöckel J, Safar J, Wallace AC, Cohen FE, Prusiner SB. Prion protein selectively binds copper(II) ions. Biochemistry 1998; 37: 7185-93
24. Kramer ML, Kratzin HD, Schmidt B et al. Prion protein binds copper within the physiological concentration range. J Biol Chem 2001; 276: 16711-9
25. Burns CS, Aronoff-Spencer E, Dunham CM et al. Molecular features of the copper binding sites in the octarepeat domain of the prion protein. Biochemistry 2002; 41: 3991-4001
26. Jackson GS, Murray I, Hosszu LL et al. Location and properties of metal-binding sites on the human prion protein. Proc Natl Acad Sci USA 2001; 98: 8531-5
27. Brown LR, Harris DA. The prion protein and copper: what is the connection? In: Massaro EJ. (ed) Handbook of Copper Pharmacology and Toxicology. Totowa: Humana, 2002; 103-13
28. Pauly PC, Harris DA. Copper stimulates endocytosis of the prion protein. J Biol Chem 1998; 273: 33107-10
29. Perera WS, Hooper NM. Ablation of the metal ion-induced endocytosis of the prion protein by disease-associated mutation of the octarepeat region. Curr Biol 2001; 11: 519-23
30. Brown LR, Harris DA. Copper and zinc cause delivery of the prion protein from the plasma membrane to a subset of early endosomes and the Golgi. J Neurochem 2003; In Press
31. Marella M, Lehmann S, Grassi J, Chabry J. Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J Biol Chem 2002; 277: 25457-64
32. Young K, Piccardo P, Dlouhy S, Bugiani O, Tagliavini F, Ghetti B. The human genetic prion diseases. In: Harris DA. (ed) Prions: Molecular and Cellular Biology. Wymondham, UK: Horizon Scientific, 1999; 139-75
33. Lehmann S, Harris DA. A mutant prion protein displays an aberrant membrane association when expressed in cultured cells. J Biol Chem 1995; 270: 24589-97
34. Lehmann S, Harris DA. Mutant and infectious prion proteins display common biochemical properties in cultured cells. J Biol Chem 1996; 271: 1633-7
35. Lehmann S, Harris DA. Two mutant prion proteins expressed in cultured cells acquire biochemical properties reminiscent of the scrapie isoform. Proc Natl Acad Sci USA 1996; 93: 5610-4
36. Chiesa R, Harris DA. Nerve growth factor-induced differentiation does not alter the biochemical properties of a mutant prion protein expressed in PC12 cells. J Neurochem 2000; 75: 72-80
37. Ivanova L, Barmada S, Kummer T, Harris DA. Mutant-prion proteins are partially retained in the endoplasmic reticulum. J Biol Chem 2001; 276: 42409-21
38. Priola SA, Chesebro B. Abnormal properties of prion protein with insertional mutations in different cell types. J Biol Chem 1998; 273: 11980-5
39. Singh N, Zanusso G, Chen SG et al. Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation. J Biol Chem 1997; 272: 28461-70
40. Zanusso G, Petersen RB, Jin T et al. Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem 1999; 274: 23396-404
41. Lorenz H, Windl O, Kretzschmar HA. Cellular phenotyping of secretory and nuclear prion proteins associated with inherited prion diseases. J Biol Chem 2002; 277: 8508-16
42. Capellari S, Parchi P, Russo CM et al. Effect of the E200K mutation on prion protein metabolism. Comparative study of a cell model and human brain. Am J Pathol 2000; 157: 613-22
43. Capellari S, Zaidi SI, Long AC, Kwon EE, Petersen RB. The Thr183Ala mutation, not the loss of the first glycosylation site, alters the physical properties of the prion protein. J Alzheimers Dis 2000; 2: 27-35
44. Gauczynski S, Krasemann S, Bodemer W, Weiss S. Recombinant human prion protein mutants huPrP D178N/M129 (FFI) and huPrP+9OR (fCJD) reveal proteinase K resistance. J Cell Sci 2002; 115: 4025-36
45. Daude N, Lehmann S, Harris DA. Identification of intermediate steps in the conversion of a mutant prion protein to a scrapie-like form in cultured cells. J Biol Chem 1997; 272: 11604-12
46. Narwa R, Harris DA. Prion proteins carrying pathogenic mutations are resistant to phospholipase cleavage of their glycolipid anchors. Biochemistry 1999; 38: 8770-7
47. Jin T, Gu Y, Zanusso G et al. The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome. J Biol Chem 2000; 275: 38699-704
48. Petersen RB, Parchi P, Richardson SL, Urig CB, Gambetti P. Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein. J Biol Chem 1996; 271: 12661-8
49. Negro A, Ballarin C, Bertoli A, Massimino ML, Sorgato MC. The metabolism and imaging in live cells of the bovine prion protein in its native form or carrying single amino acid substitutions. Mol Cell Neurosci 2001; 17: 521-38
50. Drisaldi B, Stewart RS, Adles C et al. Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither mutant nor wild-type PrP undergoes retrotranslocation prior to proteasomal degradation. J Biol Chem 2003; 278: 21732-21743
51. Aridor M, Balch WE. Integration of endoplasmic reticulum signalling in health and disease. Nat Med 1999; 5: 745-51
52. Kim PS, Arvan P. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: disorders of protein trafficking and the role of ER molecular chaperones. Endocr Rev 1998; 19: 173-202
53. Tsai B, Ye Y, Rapoport TA. Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat Rev Mol Cell Biol 2002; 3: 246-55
54. Bonifacino JS, Weissman AM. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu Rev Cell Dev Biol 1998; 14: 19-57
55. Ma J, Lindquist S. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci USA 2001; 98: 14955-60
56. Ma J, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 2002; 298: 1781-5
57. Sc-like conformation in the cytosol. Science 2002; 298: 1785-8
58. Yedidia Y, Horonchik L, Tzaban S, Yanai A, Taraboulos A. Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. EMBO J 2001; 20: 5383-91
59. Hegde RS, Mastrianni JA, Scott MR et al. A transmembrane form of the prion protein in neurodegenerative disease. Science 1998; 279: 827-34
60. Hölscher C, Bach UC, Dobberstein B. Prion protein contains a second endoplasmic reticulum targeting signal sequence located at its C terminus. J Biol Chem 2001; 276: 13388-94
61. Kim SJ, Rahbar R, Hegde RS. Combinatorial control of prion protein biogenesis by the signal sequence and transmembrane domain. J Biol Chem 2001; 276: 26132-40
62. Rutkowski DT, Lingappa VR, Hegde RS. Substrate-specific regulation of the ribosome-translocon junction by N-terminal signal sequences. Proc Natl Acad Sci USA 2001; 98: 7823-8
63. Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB, Lingappa VR. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 1999; 402: 822-6
64. Kim SJ, Hegde RS. Cotranslational partitioning of nascent prion protein into multiple populations at the translocation channel. Mol Biol Cell 2002; 13: 3775-86
65. Stewart RS, Harris DA. Most pathogenic mutations do not alter the membrane topology of the prion protein. J Biol Chem 2001; 276: 2212-20
66. Stewart RS, Drisaldi B, Harris DA. A transmembrane form of the prion protein contains an uncleaved signal peptide and is retained in the endoplasmic reticulum. Mol Biol Cell 2001; 12: 881-9